Linked Life Data

20465296

Source:http://linkedlifedata.com/resource/pubmed/id/20465296

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-5-28
pubmed:abstractText
Expedient access to a highly functionalized 2-pyrrolidinone (8), the gamma-lactam core of 20S proteasome inhibitor (-)-salinosporamide A (marizomib; NPI-0052; 1), using a regio- and stereoselective epoxide formation/reductive oxirane ring-opening strategy is presented. Notably, the sequential construction of the C-4, C-3, and C-2 stereocenters of 1 in a completely stereocontrolled fashion is a key feature of streamlining the synthesis of intermediate 12. A related strategy is also discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1520-6904
pubmed:author
pubmed:issnType
Electronic
pubmed:day
4
pubmed:volume
75
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3882-5
pubmed:dateRevised
2011-9-12
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy.
pubmed:affiliation
Nereus Pharmaceuticals, Inc., 10480 Wateridge Circle, San Diego, California 92121, USA. taotao@nereuspharm.com
pubmed:publicationType
Journal Article